dm+d

Unassigned

New Medicines

Chronic hand eczema (CHE)

Information

New molecular entity
Leo Pharma
Leo Pharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials

Category

Topical pan-Janus kinase (JAK)-inhibitor
CHE is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. It is the most common skin disorder of the hands that affects an estimated 1 – 5% of the general population with a one-year prevalence rate of approximately 10%. It is an inflammatory, non-infectious skin disorder of the hands and wrists4,9 and can cause itching, blisters, swelling and pain [1].
Chronic hand eczema (CHE)
Topical